Skip to main content

Human CD23/Fc epsilon RII Antibody

R&D Systems, part of Bio-Techne | Catalog # AF123

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
AF123
AF123-SP

Key Product Details

Species Reactivity

Validated:

Human

Cited:

Human

Applications

Validated:

Blockade of Receptor-ligand Interaction, Immunocytochemistry, Western Blot

Cited:

Immunohistochemistry, Immunohistochemistry-Paraffin

Label

Unconjugated

Antibody Source

Polyclonal Goat IgG

Product Specifications

Immunogen

Mouse myeloma cell line NS0-derived recombinant human CD23/Fc epsilon RII
Met150-Ser321
Accession # P06734

Specificity

Detects human CD23/Fc epsilon RII in direct ELISAs and Western blots.

Clonality

Polyclonal

Host

Goat

Isotype

IgG

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Scientific Data Images for Human CD23/Fc epsilon RII Antibody

CD23/Fce RII antibody in Human PBMCs by Immunocytochemistry (ICC).

CD23/Fc epsilon RII in Human PBMCs.

CD23/Fce RII was detected in immersion fixed human peripheral blood mononuclear cells (PBMCs) using 10 µg/mL Goat Anti-Human CD23/Fce RII Antigen Affinity-purified Polyclonal Antibody (Catalog # AF123) for 3 hours at room temperature. Cells were stained with the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; Catalog # NL001) and counterstained with DAPI (blue). View our protocol for Fluorescent ICC Staining of Non-adherent Cells.

Applications for Human CD23/Fc epsilon RII Antibody

Application
Recommended Usage

Blockade of Receptor-ligand Interaction

In a functional ELISA, 0.5-2.5 µg/mL of this antibody will block 50% of the binding of 500 ng/mL of human IgE to immobilized Recombinant Human CD23/Fc epsilon RII (Catalog # 123-FE) coated at 2 µg/mL (100 µL/well). At 10 μg/mL, this antibody will block >90% of the binding.

Immunocytochemistry

5-15 µg/mL
Sample: Immersion fixed human peripheral blood mononuclear cells (PBMCs)

Western Blot

0.1 µg/mL
Sample: Recombinant Human CD23/Fc epsilon RII (Catalog # 123-FE)
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Reviewed Applications

Read 1 review rated 5 using AF123 in the following applications:

Formulation, Preparation, and Storage

Purification

Antigen Affinity-purified

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CD23/Fc epsilon RII

CD23 (also named B cell differentiation antigen) is a member of subgroup II of the C-type (Ca++-dependent) lectin superfamily (1-5). Human CD23 is a 47 kDa, type II transmembrane glycoprotein that is expressed by a wide variety of cell types (6-10). The full-length receptor is 321 amino acids (aa) in length and contains a 274 aa extracellular region, a 26 aa transmembrane segment, and a 21 aa cytoplasmic domain. The extracellular region contains a C-type lectin domain and a connecting stalk with coiled-coil topography (3, 11). The lectin domain binds both protein and carbohydrate in an apparently Ca++ independent manner (11). The coiled-coil region contributes to oligomerization (11, 12). The lectin domain in human CD23 (aa 162-284) shares 64%, 62%, and 68% aa sequence identity with the lectin domains in mouse, rat, and bovine CD23, respectively. In the cytoplasmic region, two FC isoforms exist which arise from alternate start sites (6, 12). The “a” (or long) isoform begins with the sequence MEEGQYS and is constitutively expressed by B cells. It is believed to participate in IgE-mediated endocytosis (13). The “b” (or short) isoform begins with MNPPSQ and is induced on a wide variety of cell types by IL-4 (6). Fcb reportedly contributes to IgE-mediated phagocytosis (13). Fcb expressing cells include eosinophils, monocytes, visceral smooth muscle and intestinal epithelium (6, 14, 15). At least four soluble forms of CD23 are known to exist. They range in molecular weight from 25 kDa to 37 kDa, with the 25 kDa form predominating in sera (16). Soluble CD23 (sFc) is generated by metalloprotease (ADAM8; ADAM15; ADAM28) and cysteine-protease activity (16-18). Cleavage usually occurs between aa 150-160 (7, 8). It is unclear if sequential metalloprotease-cysteine protease activity is necessary for the generation of all soluble forms. Both soluble and membrane-bound CD23 show bioactivity. Ligands for CD23 include CD21, IgE, CD11b, and CD11c (19-21). CD23 binding to CD11b and Cd11c on monocytes results in oxidative product generation and proinflammatory cytokine release (21). On B cells, sCD23 induces IgE secretion by binding CD21. Conversely, secreted IgE will, in turn, bind B cell membrane CD23, rendering it unavailable for cleavage, and thus shutting down IgE production (11).

References

  1. Kijimoto-Ochiai, S. (2002) Cell. Mol. Life Sci. 59:648.
  2. Heyman, B. (2000) Annu. Rev. Immunol. 18:709.
  3. Bajorath, J. and A. Aruffo (1996) Protein Sci. 5:240.
  4. Drickamer, K. (1993) Curr. Opin. Struct. Biol. 3:393.
  5. Drickamer, K. (1999) Curr. Opin. Struct. Biol. 9:585.
  6. Yokota, A. et al. (1988) Cell 55:611.
  7. Ludin, C. et al. (1987) EMBO J. 6:109.
  8. Ikuta, K. et al. (1987) Proc. Natl. Acad. Sci. USA 84:819.
  9. Kikutani, H. et al. (1986) Cell 47:657.
  10. Letellier, M. et al. (1988) J. Immunol. 141:2374.
  11. Hibbert, R.G. et al. (2005) J. Exp. Med. 202:751.
  12. Beavuil, A.J. et al. (1992) Proc. Natl. Acad. Sci. USA 89:753.
  13. Yokota, A. et al. (1992) Proc. Natl. Acad. Sci. USA 89:5030.
  14. Belleau, J.T. et al. (2005) Clin. Mol. Allergy 3:6.
  15. Tu, Y. et al. (2005) Gastroenterology 129:928.
  16. Marolewski, A.E. et al. (1998) Biochem. J. 333:573.
  17. Fourie, A.M. et al. (2003) J. Biol. Chem. 278:30469.
  18. Karagiannis, S.N. et al. (2001) Immunology 103:319.
  19. Aubry, J-P. et al. (1992) Nature 358:505.
  20. Sarfati, M. and G. Delespeese (1988) J. Immunol. 141:2195.
  21. Lecoanet-Henchoz, S. et al. (1995) Immunity 3:119.

Long Name

Fc epsilon Receptor II

Alternate Names

CD23, CLEC4J, Fc epsilon RII, FCER2, Fcer2a, FceRII, IGEBF, Ly-42

Entrez Gene IDs

2208 (Human); 14128 (Mouse); 171075 (Rat)

Gene Symbol

FCER2

UniProt

Additional CD23/Fc epsilon RII Products

Product Documents for Human CD23/Fc epsilon RII Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Human CD23/Fc epsilon RII Antibody

For research use only

Loading...
Loading...
Loading...
Loading...